Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibitors: A retrospective single‐center study
Abstract Background Since 2015, immune checkpoint inhibitors have been a clinical treatment strategy for patients with advanced or recurrent non‐small cell lung cancer (NSCLC). However, the relationship between immune‐related adverse event (irAE) risk factors and patient clinical characteristics is...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-09-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14576 |